Tenaya Therapeutics (TNYA) on Nov. 8, 2025: FDA Places Clinical Hold on TN‑201 Trial as AHA 2025 Showcases Encouraging MyPEAK‑1 Data

8 November 2025

FDA clinical hold (Nov. 7): The U.S. Food and Drug Administration asked Tenaya to amend its MyPEAK‑1 Phase 1b/2a study of TN‑201 to standardize patient monitoring and immunosuppression management across sites. Tenaya says dosing will resume once changes are in place and does not expect data milestones to slip. Shares fell sharply after hours on the news. ^[1]
New clinical data unveiled today (Nov. 8): At AHA Scientific Sessions 2025, investigators reported interim safety and efficacy signals in six treated patients, with dose‑responsive increases in MyBP‑C protein and improvements in cardiac biomarkers and hypertrophy measures. Results were concurrently published in Cardiovascular Research. ^[2]
Independent coverage: Cleveland Clinic—an investigator site—said all six patients in this small early‑phase study “are no longer symptomatic,” while cautioning that more research is needed. ^[3]

What happened today (Nov. 8)

Tenaya Therapeutics (NASDAQ: TNYA) presented new interim results from its MyPEAK‑1 Phase 1b/2a trial evaluating TN‑201, an AAV9 gene‑replacement therapy designed to deliver a working MYBPC3 gene to cardiomyocytes for MYBPC3‑associated hypertrophic cardiomyopathy (HCM). The late‑breaking presentation in New Orleans highlighted longer‑term follow‑up for the first‑dose cohort (3E13 vg/kg) and initial readouts at the higher dose (6E13 vg/kg), with a simultaneous publication in Cardiovascular Research. ^[4]

Cleveland Clinic, which led the podium talk, summarized the early experience: six adults treated across two dose cohorts were monitored for months to >1 year; the therapy reached heart cells, increased the target protein, and thinned the heart wall. The center noted that, at this checkpoint, all six patients were no longer symptomatic—but emphasized the dataset is small and early. ^[5]

The FDA hold: what it means and what it doesn’t

Late Friday (Nov. 7), Tenaya disclosed that the FDA placed MyPEAK‑1 on clinical hold to incorporate protocol amendments that standardize site practices for patient monitoring and for managing immunosuppression associated with gene therapy. According to the company’s Form 8‑K, the request followed proactive discussions about the program’s next steps and was based primarily on data already reviewed by the trial’s DSMB in summer 2025—data that supported enrollment expansion at both studied dose levels. Tenaya says no new meaningful safety events have occurred since that DSMB review. ^[6]

Reuters reported that TNYA fell more than 20% in after‑hours trading following the hold. The company said it is working with the FDA and does not expect the hold to delay planned data releases or the broader timeline for TN‑201. ^[7]

What the new TN‑201 data show (interim, early phase)

Highlights from Tenaya’s press release and talk at AHA 2025 include:

Safety/tolerability: Single‑dose TN‑201 at 3E13 and 6E13 vg/kg was generally well tolerated; no dose‑limiting toxicities were observed. Immunosuppression was tapered in all patients. Most frequent related events were reversible, asymptomatic transaminase elevations. No declines in LVEF, clinical myocarditis, or ventricular arrhythmias were reported. ^[8]
Pharmacodynamics:Transduction and mRNA expression increased with dose. In the higher‑dose cohort, an early patient showed a ~14% MyBP‑C increase at 12 weeks, alongside >2‑fold higher transduction vs. Cohort 1 averages. ^[9]
Biomarkers & imaging: In Cohort 1 (≥52 weeks), cardiac troponin I fell ~48%–74% toward normal; NT‑proBNP improved or stabilized in most patients. Measures of hypertrophy improved, including 21%–39% reductions in left ventricular posterior wall thickness (LVPWT) and 12%–22% reductions in LV mass index (LVMI) in a majority of Cohort 1 patients at 52 weeks. Functionally, all patients improved by ≥1 NYHA class by 26 weeks; all Cohort 1 patients are now NYHA Class I. ^[10]

Context: Cleveland Clinic characterized the early experience as “promising,” while underscoring the need for continued follow‑up and larger trials. ^[11]

Trial details:MyPEAK‑1 (ClinicalTrials.gov NCT05836259) is a multi‑center, open‑label, dose‑escalating study planned to enroll up to 24 symptomatic adults with MYBPC3‑associated HCM. ^[12]

Stock snapshot: TNYA

As of the latest trade (about 01:15 UTC, Nov. 8), TNYA was at $1.28. Note: U.S. markets are closed today (Saturday).

What’s next

Company call: Tenaya will host a webcast for analysts/investors on Monday, Nov. 10, 2025, at 8:00 a.m. ET to discuss today’s AHA data and the status of the trial. Details and slides will be posted on the company’s investor site. ^[13]
Regulatory path: The clinical hold centers on operational protocol standardization, not on newly identified safety signals, according to Tenaya’s SEC filing. The company intends to resume dosing after implementing the changes at sites. Timing will depend on FDA interactions and site readiness. ^[14]
Data cadence: Tenaya plans periodic updates as longer‑term follow‑up in Cohort 1 matures and early higher‑dose results accrue, which are expected to inform late‑stage development plans. ^[15]

Why this matters

MYBPC3‑associated HCM is a prevalent genetic subset of HCM; many patients have nonobstructive disease with no disease‑specific therapies. A one‑time gene replacement that raises MyBP‑C and reverses hypertrophy, if confirmed in larger trials, could redefine care—especially if benefits persist and safety remains manageable. Today’s signals are encouraging but preliminary; the FDA hold is a near‑term operational hurdle and a key watch item for investors and patients alike. ^[16]

Sources & further reading

Reuters: “US FDA places clinical hold on Tenaya gene therapy trial” (Nov. 7, 2025). ^[17]
Tenaya press release: “Presents Promising Interim Clinical Data from MyPEAK‑1” (Nov. 8, 2025). ^[18]
Cleveland Clinic newsroom: “Initial Results from First‑in‑Human Gene Therapy for HCM” (Nov. 8, 2025). ^[19]
SEC filing: Form 8‑K (Nov. 7, 2025) detailing the FDA requests and Tenaya’s plan. ^[20]
Trial record: NCT05836259 on ClinicalTrials.gov. ^[21]

Disclosure: This article is for information purposes only and does not constitute investment advice.

References

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

View all

Raymond James Lifts Datadog Target to $205, Joining Upbeat Analyst Bets
November 8, 2025, 3:34 PM EST. Datadog (DDOG) received a bullish lift as Raymond James raised its price target from $170 to $205, signaling upside of about 7.8%. The move aligns with a wave of upgrades from Sanford C. Bernstein, Citigroup, Jefferies, and Canaccord Genuity that view the stock more favorably. MarketBeat data show a Moderate Buy consensus with an average target near $197.03. In recent trade, Datadog hovered around $190 after it beat estimates with Q3 earnings of $0.55 per share on $885.65 million in revenue and guided FY2025 to about 2.00-2.02 EPS, with Q4 2025 guidance of 0.54-0.56 EPS. Valuation remains elevated, but sentiment across analysts appears increasingly constructive.
Evercore ISI Boosts Expedia Target to $350, Signaling Upside for EXPE
November 8, 2025, 3:32 PM EST. Evercore ISI raised Expedia Group's target price from $280 to $350 and kept an outperform rating, implying about a 32.71% upside from current levels. The move comes as EXPE has seen a broad mix of broker coverage, with KeyCorp initiating coverage, Susquehanna and Oppenheimer lifting targets, Mizuho and Bank of America maintaining neutral to buy views. MarketBeat data show a Hold consensus at EXPE with an average price target of about $244.03, despite a Friday rally that pushed shares to roughly $263.73 and a 20% intraday gain. Key metrics cited include a debt-to-equity of 2.14, a 50-/200-day moving average trend higher, and a quarterly EPS beat of $7.57 on $4.41B revenue. Analysts expect roughly $12.28 EPS for the current year, reinforcing the bull case for Expedia.
Truist Trims Diodes DIOD Target to $51; Rating Stays Hold
November 8, 2025, 3:30 PM EST. Truist Financial lowered its Diodes (DIOD) price target from $54 to $51 while keeping a Hold rating. The target implies about 15% upside from Friday's close of $44.33. The stock slid to $44.33 on volume of 416,733. Market cap is $2.06B, with a P/E of 32.5 and beta of 1.65; 12-month high/low are $67.40 / $32.93. Analysts' views are mixed: Weiss Ratings Hold (c-); Wall Street Zen upgraded to Buy; Zacks to Hold. MarketBeat shows a Moderate Buy consensus with a $54.33 target. DIOD last quarter delivered $0.74 EPS on $350.37M revenue. Insider activity included CFO Brett Whitmire selling 2,000 shares and SVP Emily Yang selling 1,000 shares.
Benchmark Trims DraftKings Target to $37 Amid Mixed Analyst Views (DKNG)
November 8, 2025, 3:28 PM EST. DraftKings (DKNG) faced a pessimistic tilt from Benchmark, as the firm cut its price target from $43.00 to $37.00 while keeping a buy rating. The implied upside is about 25% from the prior close. Across the street, Morgan Stanley remains bullish with an overweight stance and a $52 target, and Mizuho lowered its target to $54 while signaling an outperform view. Susquehanna cut to $59 with a "positive" rating, and Weiss Ratings downgraded to sell. Bank of America moved from buy to neutral and slashed its target to $35. The Street's consensus sits at a Moderate Buy with an average target around $52.03 across 26 Buy, 2 Hold, 3 Sell. DKNG traded near $29.60, below its 50- and 200-day moving averages, after Q earnings miss.
Barclays Increases Montrose Environmental Group Target to $36, Upholds Overweight Rating
November 8, 2025, 3:26 PM EST. Barclays raised its price objective for Montrose Environmental Group (NYSE: MEG) from $35.00 to $36.00 in a Friday note, while maintaining an overweight rating. The new target implies about a 38% upside from the prior close. MEG has drawn other calls, including JPMorgan Chase & Co. lifting its target to $33.00 and assigning a neutral rating; several analysts show a spectrum from Buy to Sell, with a MarketBeat consensus near Hold and an average target around $34.40. The stock traded around $26.08 on the day, with volume of about 178k against a typical 471k. Fundamentals show a negative net margin yet modest ROE; revenue beat estimates last quarter. Investors will watch how Barclays' raised target interacts with earnings guidance and broader sector sentiment.